G A Davies1, A Lazo-Langner2, E Gandara3, M Rodger3, V Tagalakis4, M Louzada5, R Corpuz5, M J Kovacs5. 1. University of Calgary, Calgary, AB, Canada. Electronic address: Gwynivere.davies@albertahealthservices.ca. 2. Division of Hematology, Department of Medicine, Western University, London, ON, Canada; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada. 3. Division of Hematology, Department of Medicine, University of Ottawa-Ottawa Hospital, Ottawa, ON, Canada. 4. Division of Internal Medicine, Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada. 5. Division of Hematology, Department of Medicine, Western University, London, ON, Canada.
Abstract
INTRODUCTION: Patients with cancer are at increased risk of thrombosis, particularly those with central venous catheter (CVC) placement, which may predispose to the development of upper extremity deep vein thrombosis (UEDVT). Standard treatment includes low molecular weight heparin (LMWH) or LMWH bridged to warfarin. The direct oral anticoagulants (DOACs) have become standard of care for uncomplicated venous thromboembolism (VTE), but research in patients with cancer is ongoing. OBJECTIVES: To assess rivaroxaban monotherapy in patients with cancer who develop UEDVT due to CVC for preservation of line function, and safety outcomes of VTE recurrence, bleeding risk and death. MATERIALS AND METHODS: Patients ≥18years of age with active malignancy and symptomatic proximal UEDVT with or without pulmonary embolism (PE), associated with a CVC, were eligible. Treatment included rivaroxaban 15mg oral twice daily for 3weeks, followed by 20mg oral daily for 9weeks. Patients were followed clinically for 12weeks to assess for line function, recurrent VTE and bleeding. RESULTS: Seventy patients (47 women) were included, with mean age 54.1years. The most common malignancy was breast cancer (41%). Preservation of line function was 100% at 12weeks. The risk of recurrent VTE at 12weeks was 1.43%, with one episode of fatal PE. 9 patients (12.9%) experienced 11 total bleeding episodes. CONCLUSIONS: Rivaroxaban showed promise in treating CVC-UEDVT in cancer patients, resulting in preserved line function. However, bleeding rates and a fatal pulmonary embolism on treatment are concerning safety outcomes necessitating further study before rivaroxaban can be recommended.
INTRODUCTION:Patients with cancer are at increased risk of thrombosis, particularly those with central venous catheter (CVC) placement, which may predispose to the development of upper extremity deep vein thrombosis (UEDVT). Standard treatment includes low molecular weight heparin (LMWH) or LMWH bridged to warfarin. The direct oral anticoagulants (DOACs) have become standard of care for uncomplicated venous thromboembolism (VTE), but research in patients with cancer is ongoing. OBJECTIVES: To assess rivaroxaban monotherapy in patients with cancer who develop UEDVT due to CVC for preservation of line function, and safety outcomes of VTE recurrence, bleeding risk and death. MATERIALS AND METHODS:Patients ≥18years of age with active malignancy and symptomatic proximal UEDVT with or without pulmonary embolism (PE), associated with a CVC, were eligible. Treatment included rivaroxaban 15mg oral twice daily for 3weeks, followed by 20mg oral daily for 9weeks. Patients were followed clinically for 12weeks to assess for line function, recurrent VTE and bleeding. RESULTS: Seventy patients (47 women) were included, with mean age 54.1years. The most common malignancy was breast cancer (41%). Preservation of line function was 100% at 12weeks. The risk of recurrent VTE at 12weeks was 1.43%, with one episode of fatal PE. 9 patients (12.9%) experienced 11 total bleeding episodes. CONCLUSIONS:Rivaroxaban showed promise in treating CVC-UEDVT in cancerpatients, resulting in preserved line function. However, bleeding rates and a fatal pulmonary embolism on treatment are concerning safety outcomes necessitating further study before rivaroxaban can be recommended.
Authors: A J Muñoz Martín; E Gallardo Díaz; I García Escobar; R Macías Montero; V Martínez-Marín; V Pachón Olmos; P Pérez Segura; T Quintanar Verdúguez; M Salgado Fernández Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: M Carrier; N Blais; M Crowther; P Kavan; G Le Gal; O Moodley; S Shivakumar; V Tagalakis; C Wu; A Y Y Lee Journal: Curr Oncol Date: 2018-10-31 Impact factor: 3.677
Authors: Juan Carlos Laguna; Tim Cooksley; Shin Ahn; Nikolaos Tsoukalas; Thein Hlaing Oo; Norman Brito-Dellan; Francis Esposito; Carmen Escalante; Carme Font Journal: Support Care Cancer Date: 2022-08-06 Impact factor: 3.359
Authors: Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello Journal: Blood Adv Date: 2021-02-23
Authors: Mercedes Salgado; Elena Brozos-Vázquez; Begoña Campos; Paula González-Villarroel; María Eva Pérez; María Lidia Vázquez-Tuñas; David Arias Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 3.512
Authors: Marek Z Wojtukiewicz; Piotr Skalij; Piotr Tokajuk; Barbara Politynska; Anna M Wojtukiewicz; Stephanie C Tucker; Kenneth V Honn Journal: Cancers (Basel) Date: 2020-05-02 Impact factor: 6.639